U.S. regulators have approved the first drug to treat all forms of hepatitis C in as little as eight weeks.
The pill combination from AbbVie was approved Thursday by the Food and Drug Administration for adults without significant cirrhosis, a type of liver disease, and many patients who were not cured by prior treatment.
